TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed adult patients = 65 years old with a cytopathologically confirmed diagnosis of high-risk AML~* = 20% bone marrow blasts via bone marrow aspiration or biopsy~* The patient has not yet been treated for AML~* 1º or 2º AML patients with high-risk category features~* ECOG PS = 2~* Renal function and liver function limits.~Exclusion Criteria:~* Patient with a 'favorable' or 'better-risk' cytogenetic profile = t(15;17); t(8;21); or inv(16) or t(16;16)~* Patient has clinical symptoms suggestive of CNS leukemia and/or CSF findings for CNS leukemia~* Prior treatment with deacetylase inhibitors (DACi) including, panobinostat~* Impaired cardiac function~* Female patient who is pregnant or breast feeding~* Male patient who is not willing to use a barrier method of contraception~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Panobinostat (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* persistent Atrial Fibrillation (AF) lasting \> one month~* history of at least one AF relapse after previous electrical or Pharmacological cardioversion~Exclusion Criteria:~* left atrium size \> 6 cm~* severe valvulopathy~* myocardial infarction during the previous 6 months~* unstable angina~* NYHA heart failure class IV or hemodynamic instability~* cardiac surgery during the previous 3 months~* significant pulmonary thyroid and hepatic disease~* contraindications to treatment with amiodarone or RASS inhibitors~* chronic renal dysfunction~* QT \> 480 msec in the absence of bundle-branch block~* bradycardia \< 50 b/min~* diagnosis of paroxysmal AF~* hyperkalemia~* pregnancy~* any disease or other medical treatment that, in the opinion of the investigators, could interfere with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- n-3 PUFAs (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of any race between 18 to 70 years old (inclusive)~* Patients who gave written informed consent to participate in the study~Exclusion Criteria:~* Recipients of multi-organ transplantation~* Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA) identical living donor kidney transplantation.~* Graft cold ischemia time greater than 40 hours.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose Everolimus Group (Type: EXPERIMENTAL): 1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.
- High-dose Everolimus Group (Type: EXPERIMENTAL): 3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.
- Control Group (Type: ACTIVE_COMPARATOR): 1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Whitening Efficacy of Dentifrice Containing 10% High Cleaning Silica, 0.5% Sodium Phytate and 0.5% Sodium Pyrophosphate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18-70 years old~* Good general health~* Could attend the clinical examinations during the 8 week study period~* Possessing \>20 natural permanent teeth that were uncrowned or heavily filled with restorative materials, excluding third molars~* Having a whole-mouth mean tooth stain score of more than 1.5 according to the Lobene index.~Exclusion Criteria:~* Severe oral diseases, chronic disease or allergic to the trial products~* Advanced periodontal diseases~* Females who are pregnant or lactating~* Taking part in other clinical trials~* Taking part in orthodontic treatment or wearing removable denture~* Fluorosis or tetracycline teeth~* Receiving prophylaxis during the previous 3 months or tooth whitening treatment during the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Toothpaste containing effective ingredients (Type: EXPERIMENTAL): Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
- Negative control toothpaste (Type: PLACEBO_COMPARATOR): Use the negative control dentifrice to brush teeth twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have been positive for serum anti-human T-cell lymphotropic virus type I antibody~* Subjects with hematologically or pathohistologically confirmed as peripheral lymphoid tumor which surface antigen analysis has identified to be of T-cell origin~* Subjects who have been classified into acute subtype, the lymphoma subtype or chronic subtype with poor prognostic factors~* Subjects who have been positive for CCR4 by CCR4 expression analysis~* Subjects who have never been treated for adult T-cell leukemia-lymphoma~* Subjects who have presented enlarged lymph nodes, tumor nodules in extranodal organs, abnormal lymphocytes in peripheral blood or cutaneous lesions~* Subjects with a performance status of 0 to 2~* Subjects who have been negative for HBs antigen and anti-HCV antibody~* Subjects who have given written voluntary informed consent to participate in the study~Exclusion Criteria:~* Subjects who are scheduled for transplant therapy such as hematopoietic stem-cell transplantation~* Subjects who had myocardial infarction within 12 months before study enrollment or who have cardiac disease that may worsen during treatment with doxorubicin~* Subjects who have been positive for anti-HIV antibody~* Subjects with active multiple cancer~* Subjects with a history of allergic reactions to therapeutic antibodies~* Subjects who require emergency radiotherapy for treating the symptoms caused by bulky masses or who may require such radiotherapy after the start of the study~* Subjects who are pregnant, lactating or of childbearing potential, or who are planning to have children

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mLSG15 (Type: ACTIVE_COMPARATOR): None
- mLSG15 + KW-0761 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of one of the three subtypes of Attention Deficit Hyperactivity Disorder (ADHD) verified by both a parent/child interview and a teacher assessment using SNAP-IV questionnaires~* taking 5 - 20 mg of immediate-release methylphenidate (Ritalin®) at least twice a day, 20 - 60 mg of sustained-release methylphenidate (Ritalin-SR®) per day, or a combination of immediate-release and sustained-release methylphenidate up to a daily dose not exceeding 60 mg~* having used methylphenidate for at least 3 months at some time in the past and have been on the same dose for the previous 4-week period without any significant adverse experiences, considered to be positive responders to methylphenidate therapy, and agreeing to take only the supplied study drug as treatment for ADHD during the three-week treatment phase of the study~* able to comply with the study visit schedule and whose parent(s) and teacher are willing and able to complete the protocol-specified assessments, including behavior modification procedures~* agreeing not to ingest any caffeine containing beverages (e.g., coffee or soda) or foods (e.g., chocolate) on days 7, 14, and 21 of the study~Exclusion Criteria:~* Patients having clinically significant gastrointestinal problems, including narrowing of the gastrointestinal tract~* considered markedly anxious, tense, agitated, or depressed, having psychotic disorders, a history of seizures, or having a diagnosis of Tourette's syndrome~* whose primary treatment focus is oppositional-defiant disorder, conduct disorder, or tics, or whose primary treatment focus is other psychiatric conditions such as depressive disorders, bipolar disorders, or other mood disorders~* having a mean of two blood pressure measurements (systolic or diastolic) equal to or greater than the 95th percentile for age, sex, and height~* if female, have begun menstruation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): OROS Methylphenidate HCl
- 002 (Type: ACTIVE_COMPARATOR): Ritalin
- 003 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DSM IV defined autism and meets cut off on Autism Diagnostic Inventory-Revised (ADI-R) and/or the Autism Diagnostic Observation Scale (ADOS)~* Age 3 through 7 years~* IQ of 50 or above~* Parental agreement to continue present dietary, behavioral or psychotropic drug treatment but not change treatment during 8 week intervention~* Willingness to have blood drawn, without the use of a sedative prescription from the study doctor~Exclusion Criteria:~* Bleeding disorder~* Cancer~* Seizure disorder~* Fragile X or other known genetic cause of autism~* Perinatal brain injury (i.e.: cerebral palsy)~* Other serious medical illnesses~* Current use of any B12 supplement

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Active (Type: EXPERIMENTAL): Active Methyl B12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Amino Acid Supplement During Acute Inflammation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male gender~* 20\<BMI\<30~* Age \> 25 years old~* Written consent before starting the study~Exclusion Criteria:~* Allergy for soya products ore egg~* Diabetes~* Epilepsy~* Infection~* Immune defects~* Heart disease~* Dysregulated hypertension~* Participating in other trials using radioactive tracers or x-rays the last year.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Saline (Type: NO_INTERVENTION): Only saline is given.
- + Saline (Type: PLACEBO_COMPARATOR): Endotoxin is given + Placebo (Saline)
- + amino acids (Type: ACTIVE_COMPARATOR): Endotoxin is given + amino acids (intravenously)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of a full mutation with absence or deficient FMRP levels.~* Males and females ages 10 through 17 years~* Willingness of potential study participant as well as a parent or caretaker to participate in the protocol.~* Speech is the primary means of communication with three-word or longer utterances used on a daily basis.~* Intelligence quotient (IQ) ≤70 as measured by the Leiter- R.~* Sexually active women of childbearing potential (WCBP) must be using a medically acceptable method of birth control and have a negative qualitative serum β-human chorionic growth hormone (β-HCG) or urine pregnancy test collected at the initial screening visit.~Exclusion Criteria:~* Persons who do not speak English.~* Changes in any medications (including investigational medications) within the last month (4 weeks). All concomitant medications must have been on a stable course for at least 4 weeks prior to enrollment into the study and maintain stability throughout the course of the study.~* Changes in behavioral therapy or educational programming during the study. This does not include scheduled school holidays.~* Have any disease or condition (medical or surgical) at screening that might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.~* Patients who, in the opinion of the investigator, are unsuitable in any other way to participate in this study, including being unable to comply with the requirements of the study or displaying clinically significant abnormalities in safety assessments at screening.~* Patients on prohibited medications~* History of recurrent status epilepticus.~* Inability to withhold grapefruit and grapefruit juice from diet during the entire clinical trial.~* Subjects unwilling to abstain from alcoholic beverages during the trial.~* Subjects who are actively suicidal.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lovastatin and PILI (Type: ACTIVE_COMPARATOR): Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
- Placebo and PILI (Type: PLACEBO_COMPARATOR): Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female ≥18 years and ≤ 85 years~* colonoscopy procedure indicated~* willing to stay in the outpatient clinical site for colonoscopy and questionnaire completion~* willing and able to undergo study-related procedures~* informed consent signed by a patient for participation in the study~* negative pregnancy test in women with childbearing potential and consent for double barrier method birth control for subjects, men and women, during the study~Exclusion Criteria:~* ileus~* suspected colonic tumor with manifestations of intestinal obstruction~* delayed gastric emptying (gastroparesis), weak vomiting reflex, tendency to aspiration and regurgitation~* toxic megacolon which is a result of severe inflammatory conditions of the colon including Crohn's disease and ulcerative colitis~* suspected intestinal perforation or risk of gastrointestinal perforation~* signs of severe intestinal bleeding~* acute inflammatory anal or perianal pathology~* severe concomitant diseases of internal organs~* psychiatric diseases in aggravation stage~* hypersensitivity to polyethylene glycol and/or any component of MOVIPREP® preparation~* phenylketonuria or diagnosed glucose-6-phosphate dehydrogenate deficiency~* unconsciousness~* dehydration~* severe inflammatory diseases~* acute abdominal pain of unknown etiology~* pregnancy and lactation period~* participation in any other clinical study (including studies of experimental devices) in 30 days prior participation in the present trial~* patients who test positive for human immunodeficiency virus (HIV)/autoimmune disease (AID), Wasserman reaction (RW) or hepatitis B virus (HBC)~* any condition or circumstance that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of study data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MOVIPREP (Morning-only dose) (Type: EXPERIMENTAL): MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
- MOVIPREP (Split-dose) (Type: OTHER): MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Fluoxetine Versus Citalopram Therapy to Control Postmenopausal Vasomotor Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who attended the climacteric consultation for the first time, without prior treatment of menopausal symptoms, and who met postmenopausal criteria.~* Participants who met the criteria for vasomotor syndrome and score greater than 17 points in total MRS.~* Participants without psychiatric pathology (psychiatric illnesses such as major depression, generalized anxiety disorder, among others).~* Participants who agreed to participate and gave their written informed consent.~Exclusion Criteria:~* Participants who had contraindications to receive serotonin reuptake inhibitors (SSRIs).~* Participants who were receiving prior treatment for the postmenopausal or vasomotor syndrome.~* Participants who did not agree to participate or sign the informed consent.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluoxetine group (Type: ACTIVE_COMPARATOR): Participants received fluoxetine, 20 mg tablets, once a day for six months.
- Citalopram group (Type: EXPERIMENTAL): Participants received citalopram, 20 mg tablets, once a day for six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete